Syngene International Q2 Review: Upgraded to ‘Neutral’ by Yes Securities
Syngene International’s Q2 performance review, upgraded to ‘Neutral’ by Yes Securities, and its implications for Indian investors and traders.
Blog
indian stock market
Blog
Bharti Airtel Shares Drop 4% as Singtel Offloads Stake Worth Rs 10,915 Crore
Bharti Airtel’s shares fell over 4% after Singtel reportedly offloaded a stake worth Rs 10,915 crore, sparking concerns among investors about the company’s future prospects.
Blog
Bharat Electronics Share Price Rebounds After Receiving Rs 6,650-Crore Order from NTPC
Bharat Electronics Ltd. share price rebounded after the company received a major order worth Rs 6,650 crore from NTPC Ltd. for engineering, procurement, and construction work in Odisha.
Blog
GSK Pharma Q2 Review: Temporary Hiccups Lead To Muted Show On A YoY Basis
GSK Pharma reported lower-than-expected revenue for Q2 FY26, but controlled costs resulted in improved profitability. Get the latest updates on the Indian stock markets and GSK Pharma’s performance.
Blog
Vodafone Idea Q2 Results: Date, Earnings Call Schedule, and Share Price History
Vodafone Idea is set to declare its Q2FY26 results next week. Check the date, earnings call schedule, and share price history to make informed investment decisions.
Blog
MAS Financial Q2 Review: Axis Securities Maintains ‘Buy’ Call Amidst Green Shoots of Growth and Improving Asset Quality
Get the latest updates on MAS Financial Services’ Q2 performance, Axis Securities’ ‘Buy’ recommendation, and the outlook for the NBFC sector in India.
Blog
India and China: Two Different Markets with Unique Opportunities
Mark Matthews, Head of Research Asia at Julius Baer, discusses the differences between the Indian and Chinese markets, and how both can continue to grow in parallel.
Blog
Lenskart IPO: Ambit Initiates Coverage with Sell Rating, Cites Valuation Concerns
Lenskart, set to list on Monday, receives its first sell rating from Ambit due to valuation concerns and a capital-intensive business model.
Blog
Hindalco Q2 Results: Strong Performance by India Business Drives 21% Profit Growth
Hindalco Industries Ltd reports a 21.2% rise in consolidated profit after tax at Rs 4,741 crore in Q2, driven by strong performance by the India business and disciplined cost management.
Blog
Indoco Remedies Q2 Review: Dolat Capital Revises Target Price, Sees 15% Downside
Indoco Remedies Ltd.’s Q2 FY26 earnings came above estimates, but Dolat Capital has downgraded its FY26E/FY27E Ebitda estimates, maintaining a ‘Sell’ rating with a revised target price.